Quince Therapeutics Inc.

QNCX | NASDAQ

Price Alert Chart Builder DCF Calculator

$31.35

+$0.35 (+1.13%)

At close: Sep 22, 2026, 4:00 PM ET

$32.52

+$1.17 (+3.73%)

After-hours: Sep 22, 2026, 7:43 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.13%

(1D)

Rating

Updated: Sep 19, 2026

33.2

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $8.73M

1D Range

30.50 32.79

52W Range

15.10 910

Valuation (TTM)

PE -0.45

PB 0.08

EV/EBITDA 1.40

Valuation (NTM)

Forward PE N/A

Forward PEG 0.01

Price Target $69

Cash Flow

FCF Yield -544.6%

SBC Adj. FCF Yield -727.9%

SBC Impact -33.7%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 51.3% | 36.2%

FCF 3Y | 5Y -25.5% | 4.2%

Returns

ROA -74.6%

ROE -413.3%

ROIC -104.6%

Financial Health

Net Cash

$115.98M

Current Ratio 14.52

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive ...

Sector Healthcare

Industry Biotechnology

Employees 38

IPO Date May 8, 2019

Website www.quincetx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

$69

Upside

+120.10%

Buy (2)

Hold (2)

Sell (0)

Analyst Details ➞